CORPORATE FACT SHEET
ZymoGenetics
creates novel protein drugs with the potential
to significantly help patients fight their
diseases.
History
ZymoGenetics, Inc. was founded in June 1981 by three noted university
professors: Earl W. Davie, Professor of
Biochemistry at the University of Washington;
Benjamin D. Hall, Professor of Genetics
at the University of Washington; and the
late Michael Smith, Professor of Biochemistry
at the University of British Columbia and
1993 Nobel Laureate. In 1988, Novo Nordisk
acquired the company and for the next twelve
years ZymoGenetics operated as the U.S.
research arm of Novo Nordisk. In November
of 2000, ZymoGenetics became an independent
company, and in February of 2002, ZymoGenetics
completed its initial public offering, raising
$120M.
Chief Executive Officer: Bruce L.A. Carter, Ph.D.
President: Douglas E. Williams, Ph.D.
Cash Position: The Company's
cash, cash equivalents and short-term investments
totaled approximately $155 million (as of
3/31/08).
2007 Revenues: $38.5 million
Number of Shares Outstanding: approx. 68.7 million (as of 4/11/08)
Stock Exchange Listing: NASDAQ: ZGEN
Number of Employees: 535 (as of 2/13/08)
Discovery efforts: ZymoGenetics
has a growing pipeline of potential product candidates that includes proteins, antibodies and antibody-like molecules.
Product Candidates:
Recombinant Thrombin (rThrombin) -
for use as a general hemostat
Atacicept (formerly referred to as
TACI-Ig) - as a potential treatment for
autoimmune diseases and B-cell malignancies
IL-21 - as a potential treatment for cancer
PEG-interferon lambda (IL-29) - as a potential treatment for hepatitis C
Key Partnerships:
Partnered with Novo Nordisk to develop IL-21
Co-development collaboration with Merck Serono for atacicept
Important Dates:
1981 Company founded
1988 ZymoGenetics acquired by Novo Nordisk
2000 Novo Nordisk spins off ZymoGenetics
2002 ZymoGenetics completes IPO
2003 Initiates clinical trials of atacicept and rThrombin
2004 Starts clinical development of IL-21
2004 Opens Earl Davie Building II with
clinical manufacturing facility
2004 Enters into broad strategic alliance with Serono
2005 Designates PEG-interferon lambda as product candidate
2006 Completes rThrombin Phase 3 clinical trial and files BLA
2007 Enters into partnership with Bayer HealthCare to co-commercialize rThrombin
2008 FDA approves RECOTHROM™ Thrombin, topical (Recombinant) for sale
Corporate Headquarters
1201 Eastlake Ave. E, Seattle WA 98102 Tel: 206-442-6600
Web Site Address: www.zymogenetics.com
|
Back to top
